Edesa Biotech, Inc. EDSA
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +71.83%
- 1 year
- +31.18%
- Open
- 2.57
- Prev close
- 2.57
- Mkt cap
- 32.97M
- Vol
- 44.78K
- Avg vol
- 56.98K
- EPS
- -1.72
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.40
- High
- 2.61
- Forward P/E
- -0.89
- Beta
- 0.84
- Short ratio
- 0.76
- Inst. own
- 12.20%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 14, 2025
- 50-d avg
- 2.66
- 200-d avg
- 4.02
- 1y target
- 20.50
News
1 week ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 19.3% to $1.14 during Tuesday's after-market session. The company's market cap stands at $1.8 million. Edesa Biotech (NASDAQ:EDSA)…
-
2 weeks ago benzinga.com
Edesa Biotech Receives FDA Clearance For Its Investigational New Drug Application For Its Phase 2 Clinical Trial Of EB06 In Vitiligo
Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported that the U.S. Food and…
2 weeks ago globenewswire.com
Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers SCWorx Corp. - Common Stock (NASDAQ:WORX) shares moved upwards by 48.8% to $6.25 during Thursday's after-market session. XORTX Therapeutics (NASDAQ:XRTX) stock increased by 22.7% to $2.27.…
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 142.1% to $13.0 during Monday's after-market session. The company's market cap stands at $5.1 million. Picard Medical (AMEX:PMI) stock…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Circle8 Group (NASDAQ:CIRC) shares increased by 18.2% to $0.77 during Thursday's pre-market session. The company's market cap stands at $60.1 million. The company's, Q2 earnings came out…
2 months ago benzinga.com
Edesa Biotech Stock Sinks After Fresh Capital Raise
Edesa Biotech Stock falls in premarket trading as investors weigh a $25 million offering, new warrants and potential dilution.
2 months ago globenewswire.com
Edesa Biotech Announces Pricing of $25.0 Million Public Offering
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market session. The market value of their outstanding shares is at $7.2 million. The company's, Q4 earnings…
-
2 months ago benzinga.com
Edesa Biotech Commences Common Stock Offering; Terms Undisclosed
Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today…
2 months ago globenewswire.com
Edesa Biotech Announces Proposed Public Offering
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…
-
2 months ago benzinga.com
Edesa Biotech Q3 EPS $(0.60) Misses $(0.58) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.58) by 3.45 percent. This is a 140 percent decrease over losses of…
2 months ago globenewswire.com
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
4 months ago globenewswire.com
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
5 months ago benzinga.com
Edesa Biotech Announces Exploratory Data For Its Anti-TLR4 Monoclonal Antibody Paridiprubart In Patients With Acute Kidney Injury And Respiratory Distress; Analyses Demonstrate Mortality Reduction
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for…
5 months ago globenewswire.com
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
5 months ago globenewswire.com
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
5 months ago benzinga.com
Edesa Biotech Q2 EPS $(0.49) Misses $(0.26) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.26) by 88.46 percent. This is a 63.33 percent decrease over losses of…
5 months ago globenewswire.com
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
7 months ago globenewswire.com
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients Selection Follows Positive Phase 3 Results for Paridiprubart…
-
7 months ago benzinga.com
Edesa Biotech Reaffirms Enrollment Timeline Guidance For Phase 2 Clinical Study Of EB06 In Moderate-To-Severe Nonsegmental Vitiligo
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today provided an update on…
7 months ago globenewswire.com
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
8 months ago benzinga.com
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Box Inc (BOX) shares jump 6.2% in pre-market trading after beating earnings expectations with $305.88M in revenue and 49 cents per share earnings.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
8 months ago benzinga.com
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
8 months ago benzinga.com
Reported Earlier: Edesa Biotech Reports Phase 3 Data Show Paridiprubart Cuts 28-Day Mortality To 24% From 33% Across 278 Patients; Targeting Sepsis, Acute Kidney Injury And Pneumonia With New Patent Filings
Results in a population of 278 patients affirm statistically significant mortality reductions
-
8 months ago benzinga.com
Edesa Biotech Announces Additional Data From Phase 3 Study Of Paridiprubart
Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files…
8 months ago globenewswire.com
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
8 months ago gurufocus.com
Market Today: AI Fears Rattle Stocks; CPI Cools, Rivian Pops
Guru Stock PicksRobert Bruce has made the following transactions:Reduce in NEE by 1.49%Ray Dalio has made the following transactions:Reduce in CNX by 13.43%Sold
-
8 months ago benzinga.com
Edesa Biotech Q1 EPS $(0.28) Beats $(0.45) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.45) by 37.78 percent. This is a 41.67 percent increase over losses of…
8 months ago globenewswire.com
Edesa Biotech Reports Fiscal 1st Quarter 2026 Results
TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
-
10 months ago benzinga.com
Edesa Biotech Q4 EPS $(0.32) Misses $(0.27) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.27) by 19.85 percent. This is a 10.34 percent decrease over losses of…
10 months ago globenewswire.com
Edesa Biotech Reports Fiscal Year 2025 Results
TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session